Cell Cycle Deregulation in Cancers

Guest Editor:

Dr. Rebecca S. Hartley
Department of Cell Biology and Physiology; MSC08-4750; University of New Mexico; Albuquerque, NM 87131, USA
rhartley@salud.unm.edu

Deadline for manuscript submissions: closed (15 October 2013)

Message from the Guest Editor

Dear Colleagues,

Loss of normal cell cycle control is a hallmark of cancer, resulting in targeting of cell cycle regulators for cancer therapy. In general, strategies used to exploit the deregulated cancer cell cycle by directly targeting cell cycle regulators do not provide cancer specificity. This issue of Cancers invites contributions of original research reports, clinical studies, and review articles that focus on cancer specific modifications that would allow indirect targeting of cell cycle deregulation. Potential topics include modifications of the microenvironment, inflammatory signaling, stress response, and post-transcriptional events that result in cell cycle deregulation.

Dr. Rebecca S. Hartley
Guest Editor
Message from the Editor-in-Chief

Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews. Citations available in PubMed, full-text archived in PubMed Central. Indexed in BIOSIS Previews, Scopus and other databases.

CiteScore 2017 (Scopus): 5.82, which equals rank 26/223 (Q1) in the 'Oncology' category and 23/191 (Q1) in the 'Cancer Research' category.